Dianthus Therapeutics, Inc.
DNTH
NASDAQ·Healthcare·Biotechnology·Mkt cap $6.0B
$108.10
▲ +0.23%
P/E
-831.54
Mkt Cap
$6.0B
52-Wk Range
$25.00–$117.88
52-Week Range
$25.00 - $117.88
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 239.9% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary monoclonal antibody platform technology
- Focus on underserved rare autoimmune and neurological diseases
- Clinical-stage asset with potential for expedited regulatory pathways
Bear Case
1 risk
- Low volatility (beta 0.1).
Growth
Stable outlook
Phase 1 clinical trial advancement of DNTH103
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+33.1% over 3m
Quality
Excellent
Strong fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying DNTH right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 4, 2026
AUG 4, 2026
Reported EPS of -$0.90 vs -$0.85 consensus (-6.3% surprise). Revenue of $761.0K vs $297.2K expected (+156.1%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-6.3%
Revenue trend · last 8Q
—
+190%
+33%
-90%
-82%
-79%
-60%
+294%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$2.2M
$1.3M
$1.2M
$193.0K
$396.0K
$284.0K
$463.0K
$761.0K
Margins · last 8Q
Gross
100.0%
Profit
-6598.6%
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Sep 4, 2026
vs Industry
How DNTH stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related